What is the recommended dosing, dose adjustments, drug interactions, and monitoring for tivozanib in adult patients with advanced solid tumors?

Tivozanib: Dosing, Adjustments, Interactions, and Monitoring

Recommended Dosing

Tivozanib is dosed at 1.5 mg orally once daily for 21 consecutive days followed by 7 days off treatment in a 28-day cycle, continuing until disease progression or unacceptable toxicity. 1, 2

• The medication should be taken with or without food, but avoid high-fat meals 3
• Tablets must be swallowed whole and should not be split, crushed, or chewed 3
• This 4-week-on, 2-week-off regimen was established as the maximum tolerated dose in phase I trials 1

FDA-Approved Indication

Tivozanib received FDA approval in March 2021 specifically for patients with relapsed or refractory advanced renal cell carcinoma (RCC) who have received 2 or more prior systemic therapies 4, 2. The NCCN guidelines classify tivozanib as a Category 2A, other recommended subsequent therapy option for patients with clear cell RCC 4.

Dose Adjustments for Adverse Events

Common Toxicities Requiring Management

The most frequent grade 3-4 adverse reaction is hypertension (24%), which is significantly more manageable than with comparator agents 2. Other notable adverse events include:

• Hypertension (most common grade ≥3 event at 24%) 2
• Diarrhea, rash, and palmar-plantar erythrodysesthesia occur at lower rates compared to sorafenib 2
• Treatment-related adverse events led to dose reduction in only 17% and discontinuation in 32% of patients 5

Dose Modification Strategy

Tivozanib demonstrates lower rates of dose reduction, interruption, or permanent discontinuation compared to sorafenib, making it particularly suitable for heavily pretreated patients 2, 6. When adverse events occur:

• Dose reductions and interruptions are less frequently required than with alternative VEGFR TKIs 2
• Prior immunotherapy does not impact dose modification rates 6
• The long half-life of 4.7 days allows for flexible dosing adjustments 1

Drug Interactions

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (like ketoconazole) do NOT cause clinically significant changes in tivozanib pharmacokinetics, so dose adjustment is not required when co-administered 7. However, the FDA label for a different drug (ivosidenib) recommends reducing dose with strong CYP3A4 inhibitors and monitoring for QTc prolongation 3.

CYP3A4 Inducers

Avoid concomitant use of strong CYP3A4 inducers (like rifampin) with tivozanib, as they significantly decrease tivozanib exposure by enhancing CYP3A4-mediated metabolism 7. Co-administration with rifampin caused:

• Significant decrease in area under the curve and half-life
• Increased clearance of tivozanib
• Reduced therapeutic efficacy 7

QTc-Prolonging Drugs

Tivozanib has minimal effect on cardiac repolarization, with a maximum QTcF change of only 9.3 milliseconds at therapeutic doses 8. However:

• Avoid concomitant use with other QTc-prolonging medications when possible 3
• If co-administration is unavoidable, monitor ECGs closely 3
• No QTcF values >500 milliseconds were observed in clinical trials 8

Monitoring Requirements

Cardiovascular Monitoring

Obtain baseline and periodic electrocardiograms (ECGs) and electrolyte panels throughout treatment 3, 8:

• Monitor for QTc interval prolongation, though risk is minimal 8
• Check blood pressure regularly given 24% incidence of grade 3-4 hypertension 2
• No significant changes in heart rate, PR interval, or QRS complex are expected 8

Laboratory Monitoring

Perform routine blood tests before starting and during treatment to monitor for:

• Kidney function (creatinine) 4
• Liver function tests (transaminases, bilirubin) 1
• Complete blood counts 4
• Electrolytes (particularly sodium, potassium, phosphate, magnesium) 3

Neurologic Monitoring

Monitor patients for new motor and/or sensory findings suggestive of Guillain-Barré syndrome, though this is rare 3. Permanently discontinue tivozanib if Guillain-Barré syndrome is diagnosed 3.

Clinical Context and Positioning

Treatment Sequencing

Tivozanib is positioned after failure of both VEGFR TKIs and immune checkpoint inhibitors 4. The TIVO-3 trial demonstrated:

• Improved progression-free survival (5.6 vs 3.9 months) compared to sorafenib 4, 2
• Similar overall survival (HR 0.97) 4, 2
• 26% of patients had prior immuno-oncology therapy 6

Long-Term Outcomes

Patients who remain progression-free at 12 months on tivozanib show significant overall survival benefit (HR 0.45; P = 0.0221) compared to sorafenib 6. Landmark long-term PFS rates favor tivozanib:

• 3-year PFS: 12.3% vs 2.4% with sorafenib
• 4-year PFS: 7.6% vs 0% with sorafenib 6

Real-World Considerations

In heavily pretreated patients (median 4 prior therapies, all with prior ICT, 87% with prior cabozantinib), tivozanib yields modest clinical benefit with a 23.3% clinical benefit rate and median PFS of 3.8 months 9. This represents a reasonable option when other therapies have been exhausted, though expectations should be tempered in this heavily pretreated population 9.